Company Overview - Molina Healthcare, Inc. (MOH) is based in Long Beach, California, and provides managed healthcare services to low-income families and individuals under Medicaid and Medicare programs, as well as through state insurance marketplaces. The company has a market capitalization of $7.3 billion and operates health plans in California, Washington, Utah, and Michigan, along with primary care clinics in Northern and Southern California [1] Earnings Expectations - Analysts anticipate that MOH will report a profit of $1.68 per share on a diluted basis for the fiscal first quarter of 2026, representing a significant decline of 72.4% from $6.08 per share in the same quarter last year [2] - For the full fiscal year, the expected EPS is $5.03, down 54.4% from $11.03 in fiscal 2025, but is projected to rise by 65.2% year over year to $8.31 in fiscal 2027 [3] Earnings History - In the previous quarters, MOH's earnings have shown volatility, with reported EPS of $6.08, $5.48, $1.84, and a loss of $2.75 for the quarters ending in March, June, September, and December 2025, respectively. The company has missed consensus estimates in three of the last four quarters [4] Stock Performance - MOH stock has underperformed significantly, with a decline of 57.1% over the past 52 weeks, contrasting with the S&P 500 Index's gain of 13.4% during the same period [5] - Following the Q4 results reported on February 5, where adjusted losses of $2.75 missed expectations, the stock fell by 25.5% in the subsequent trading session [6] Analyst Ratings - The consensus opinion among analysts on MOH stock is cautious, with a "Hold" rating overall. Out of 18 analysts, 2 recommend a "Strong Buy," 13 suggest a "Hold," 1 advises a "Moderate Sell," and 2 advocate a "Strong Sell." The average analyst price target is $144.40, indicating a potential upside of 4% from current levels [7]

Core Insights - Molina Healthcare, Inc. (NYSE:MOH) is recognized as one of the best stocks to buy according to billionaire Seth Klarman, with a new addition of over 620,000 shares in the Baupost Group's 13F portfolio [1] - The company projected 2026 premium revenue to be approximately $42 billion, slightly lower than 2025, with Medicaid rates expected to average around 4%, not offsetting a projected medical cost trend of 5% [1] - CEO Joseph Zubretsky announced a Medicaid contract win in Florida, expected to yield $6 billion in annual run rate premium, going live in late 2026, and highlighted an active pipeline of $50 billion in new opportunities [3][4] Financial Projections - Management's guidance for 2026 includes a decline in Marketplace premium by 50% and a combined headwind of $1 per share from Medicare and Marketplace segments [1] - The company provides managed healthcare services to low-income families and individuals under Medicaid and Medicare programs, as well as through state insurance marketplaces in the U.S. [4]

Core Insights - Redwood Capital Management disclosed a purchase of 51,600 shares of Molina Healthcare, valued at approximately $8.48 million based on quarterly average pricing [1][2] - The total position in Molina Healthcare increased to 110,000 shares, with a quarter-end value of $19.09 million, reflecting a net position change of $7.91 million due to price appreciation [2] Company Overview - Molina Healthcare is a leading provider of managed healthcare services, focusing on government-sponsored programs such as Medicaid and Medicare [6] - The company generated $45.43 billion in revenue over the trailing twelve months (TTM) and reported a net income of $472 million [4] Financial Performance - Molina Healthcare's stock price was $148.79, down 53% over the past year, significantly underperforming the S&P 500, which increased by about 19% during the same period [8] - The company faced a decline in profitability, with adjusted EPS falling to just over $11 from $22.65 the previous year, as the fourth quarter resulted in a loss [10] Market Position and Strategy - Molina Healthcare serves approximately 5.1 million members through a scalable, capitated payment structure, primarily targeting low-income families and individuals [9] - The company is positioned defensively within Redwood Capital's portfolio, contrasting with higher-growth, higher-volatility investments [11] - Guidance for 2026 anticipates a 2% year-over-year decline in premium revenue to about $42 billion, with adjusted earnings per share projected to be at least $5 as the company navigates contract resets [11]

Core Viewpoint - Molina Healthcare, Inc. is experiencing significant stock price declines and underperformance compared to its peers, raising concerns among analysts regarding its future prospects [3][6][8]. Company Overview - Molina Healthcare, Inc. is based in Long Beach, California, and provides managed healthcare services to low-income families and individuals under Medicaid and Medicare programs, as well as through state insurance marketplaces in the U.S. The company has a market capitalization of $7.5 billion and operates through various segments including Medicaid, Medicare, Marketplace, and Other [1]. Stock Performance - The stock reached a 52-week high of $359.97 on April 4, 2025, but has since declined by 59.3% from that peak. Over the past three months, the stock has decreased by 8.9%, underperforming the State Street Healthcare Select Sector SPDR ETF (XLV), which declined by 1.8% during the same period [3][6]. - Over the past 52 weeks, Molina's shares have dropped by 52.5%, while XLV has increased by 2.9%, indicating a significant underperformance [6]. Earnings Report - On February 6, 2025, the stock fell by 25.5% following the release of Q4 2025 earnings. The company's revenue grew by 8.3% year-over-year to $11.4 billion, exceeding forecasts. However, the adjusted loss per share was $2.75, down from an EPS of $5.05 in the previous year, which did not meet Wall Street estimates. Additionally, the full-year revenue guidance was below analysts' expectations, further eroding investor confidence [7]. Peer Comparison - Compared to its peer, Centene Corporation (CNC), which has declined by 40.3% over the past 52 weeks, Molina Healthcare has shown weaker performance. Among 18 analysts covering Molina, the consensus rating is a "Hold." Although the stock trades at a premium to its mean price target of $144.40, the highest price target of $180 suggests a potential upside of 22.9% [8].

Core Viewpoint - Centene Corporation is facing challenges due to a decline in membership numbers for certain Affordable Care Act plans, impacting investor sentiment and stock performance [3][5]. Company Overview - Centene Corporation (NYSE:CNC) is a healthcare company that provides services to government-sponsored healthcare programs, focusing on under-insured and uninsured individuals. It operates in two segments: Managed Care and Specialty Services, competing with healthcare giants like UnitedHealth Group and Anthem [1]. Stock Performance - Ann Hynes from Mizuho Securities set a price target of $41 for CNC, indicating a potential increase of about 12.64% from the current trading price of $36.40 [2][5]. - Centene's shares recently dropped by as much as 13% following announcements about a decrease in membership numbers for certain Affordable Care Act plans [3][5]. - The stock price fluctuated between a low of $36.28 and a high of $42.45, indicating market volatility [3]. - Over the past year, CNC has seen a high of $66.03 and a low of $25.08, with a current market capitalization of approximately $17.9 billion and a trading volume of 16,635,093 shares [4].

Core Viewpoint - Humana Inc. has successfully completed a public offering of $1.0 billion in junior subordinated notes, which will mature in 2056 and carry a fixed interest rate of 6.625 percent [1] Group 1: Offering Details - The total principal amount of the junior subordinated notes offering is $1.0 billion [1] - The expected net proceeds from the offering are approximately $986 million after accounting for underwriters' discounts and estimated offering expenses [1]

Core Insights - Health Net has awarded $31.25 million in grants to develop 10 new affordable housing projects across four counties in California, aiming to provide at least 900 new affordable housing units [1][2] - The funding represents 84% of Health Net's planned $37 million investment to expand low-income housing units, highlighting the company's commitment to addressing housing insecurity for vulnerable populations [2] - Since 2020, Health Net has dedicated a total of $93 million to initiatives related to housing and homelessness [2] Housing Projects Overview - The ten funded housing projects are located in Los Angeles, Sacramento, San Joaquin, and Stanislaus counties, with specific allocations including $10 million for the LA4LA Guarantee Tool and $4 million for Morris Village in Stanislaus County [5][6][7] - The projects aim to improve health outcomes by providing secure living environments, which can help individuals manage chronic conditions and access public services [3][4] Community Impact - Health Net's investment is seen as a crucial step towards ensuring families have access to safe and stable homes, which can lead to improved health, educational opportunities, and economic stability [4] - The funding is expected to strengthen community ties and provide lasting partnerships that ensure resources reach those in need [4][8]

Financial Data and Key Metrics Changes - In Q4 2025, total revenue was $950.5 million, a 43% increase year-over-year, while adjusted EBITDA was $52.5 million, up 50% year-over-year [7][24] - For the full year 2025, revenue reached $3.2 billion, adjusted EBITDA totaled $205.4 million, and free cash flow was $104.5 million, each a record for the company [8][25] - Since 2019, revenue has grown by 467%, representing a 34% compound annual growth rate, while adjusted EBITDA increased by 279% or 25% annually [8][9] Business Line Data and Key Metrics Changes - Membership in value-based care arrangements reached 1.6 million, with mid-single-digit growth in Medicare Advantage membership year-over-year [9][10] - California revenue grew 50% year-over-year, while revenue outside California grew 90% year-over-year, indicating strong performance in both core and expansion markets [10][11] Market Data and Key Metrics Changes - Approximately 19% of total revenue was generated from membership outside California, reflecting geographic diversification [10] - The company expects approximately 80% of revenue and more than 36% of membership to be in full risk arrangements by the end of Q1 2026 [12] Company Strategy and Development Direction - The company aims to build a leading patient-centered, payer-agnostic healthcare platform, focusing on high-quality, accessible care [5][6] - The strategy includes disciplined membership growth, measured risk progression, and leveraging technology for operational efficiency [17][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate regulatory changes and market volatility, emphasizing the strength of its care model and technology platform [21][22] - The company anticipates continued disciplined membership growth and stable medical cost performance into 2026, with revenue guidance between $3.8 billion and $4.1 billion [29][30] Other Important Information - The company is addressing a material weakness in internal controls over financial reporting related to acquisition processes, with no material misstatement reported [23] - The board has increased the maximum share repurchase amount from $50 million to $100 million, reflecting confidence in long-term business value [27][28] Q&A Session Summary Question: Expectations of cost trends for 2026 - Management expects a conservative cost trend of just over 5% for 2026, with Medicare Advantage slightly lower and Medicaid and Commercial slightly higher [33][35] Question: Clarification on 2026 EBITDA guidance range - The guidance range reflects a consistent percentage of the midpoint, with expected contributions from Prospect Health synergies and forward contract rates [37][42] Question: Impact of Medicare Advantage rate notice on 2027 targets - Management believes the company will be less impacted by the rate notice compared to the industry, expecting a positive 2.5%-3% impact [46][49] Question: Integration and revenue from Prospect Health - Approximately 10%-15% of Prospect revenue is fee-for-service, with strong provider engagement and retention [55][56] Question: AI tools and their impact on operations - The company is developing AI tools to improve efficiency and reduce administrative burdens, which are expected to enhance performance and scalability [59][62] Question: Care Enablement business pipeline and margins - The Care Enablement business has a strong pipeline, with expected EBITDA margins in the 20%-25% range going forward [67]

4Q and YE 2025 Earnings Presentation February 2026 Copyright © 2025 agilon health. Confidential internal document containing proprietary information. Do not distribute. Disclaimers and Forward-Looking Statements FORWARD-LOOKING STATEMENTS AND OTHER INFORMATION Statements in this presentation that are not historical factual statements are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended ...

Group 1 - Molina Healthcare Inc. (NYSE:MOH) is considered one of the most undervalued mid-cap stocks currently available for investment [1] - Goldman Sachs lowered its price target for Molina Healthcare to $124 from $167 while maintaining a Neutral rating after the company's Q4 2025 earnings miss [1][4] - UBS analyst AJ Rice also reduced the price target for Molina Healthcare to $145 from $170, citing challenges in the Medicaid and exchanges backdrop while keeping a Neutral rating [3] Group 2 - The return profiles for strong operators in low-margin, government-priced cyclical businesses, such as managed care organizations, can diminish rapidly during economic downturns [2] - Goldman Sachs anticipates that challenges in the managed care sector will persist due to its sensitivity to the current cyclical environment [2]